Schuster H P
Medizinische Klinik I, Städtisches Krankenhaus Hildesheim, Germany.
Intensive Care Med. 1993;19 Suppl 1:S16-8. doi: 10.1007/BF01738945.
In the development of sepsis DIC is a common complication. Several studies presented in this paper show a coincidence between the development of DIC and depletion of Antithrombin III, a serine protease inhibitor which inhibits a large scale of activated clotting factors. It seems very probable that substitution therapy should be of benefit in the treatment of sepsis-related DIC and may improve the outcome of septic patients. Physiological and clinical findings are put together to clarify the basic rationale for running clinical trials and future studies.
在脓毒症的发展过程中，弥散性血管内凝血（DIC）是一种常见的并发症。本文中呈现的多项研究表明，DIC的发生与抗凝血酶III的消耗存在相关性，抗凝血酶III是一种丝氨酸蛋白酶抑制剂，可抑制多种活化的凝血因子。替代疗法在治疗脓毒症相关的DIC中似乎很可能有益，并可能改善脓毒症患者的预后。综合生理和临床研究结果以阐明开展临床试验和未来研究的基本原理。
